Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Holdings
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
Appointed director
Inv. presentation
CC transcript
Asset disposition
Cyclacel Pharmaceuticals, Inc. (CYCC) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/10/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/09/2023 8-K Quarterly results
Docs: "Cyclacel Pharmaceuticals Reports SECOND quarter financial results and provides business update"
07/24/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
07/07/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
07/03/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/03/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/03/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/03/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/03/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/03/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/03/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/03/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/03/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
05/11/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/11/2023 8-K Quarterly results
Docs: "Cyclacel Pharmaceuticals Reports first quarter financial results and provides business update"
05/04/2023 8-K Quarterly results
04/28/2023 ARS Form ARS - Annual Report to Security Holders:
04/28/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/28/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/09/2023 8-K Other Events  Interactive Data
03/08/2023 10-K Annual Report for the period ended December 31, 2022
03/06/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Cyclacel Pharmaceuticals Reports fourth quarter and full year 2022 financial results and provides business update"
02/13/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/06/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/02/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
02/02/2023 4 Rombotis Spiro George (President and CEO) has filed a Form 4 on Cyclacel Pharmaceuticals, Inc.
Txns: Granted 57,600 shares @ $0
02/02/2023 4 Kirschbaum Mark (Chief Medical Officer) has filed a Form 4 on Cyclacel Pharmaceuticals, Inc.
Txns: Granted 31,200 shares @ $0
01/26/2023 SC 13G/A ACORN BIOVENTURES, L.P. reports a 10% stake in Cyclacel Pharmaceuticals, Inc.
01/06/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
12/30/2022 8-K Quarterly results
12/09/2022 8-K Quarterly results
11/10/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/09/2022 8-K Quarterly results
10/31/2022 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy